September 1 2020 | Targeted Therapies in Oncology

Deferred Cytoreductive Nephrectomy Plus Sunitinib Bests Immediate Surgery in RCC

September 22, 2020

Clinical Articles

In a post hoc analysis of the randomized phase 3 SURTIME trial of patients with metastatic renal cell carcinoma, early treatment with sunitinib demonstrated better control over the disease as well as detection of progression before planned cytoreductive nephrectomy.

Investigators Attempt to Uncover Basis Behind Sexual Dysmorphic and Age-Related Responses to Immunotherapy

September 17, 2020

Clinical Articles

An analysis of patient samples from The Cancer Genome Atlas indicated a possible connection between tumor responses to immunotherapy and patient baseline characteristics after investigators discovered evidence of stronger immune selection by female and younger patients in early tumorigenesis.

Previous Liver Infection Requires a Rapid and Flexible Treatment Response in NSCLC

September 16, 2020

Jorge A. Rios, MD, a medical oncologist at Zangmeister Cancer Center in Columbus, Ohio, part of the American Oncology Network, shared the case of a woman who developed multiple severe adverse events attributable to durvalumab.

More Analysis Is Needed of COVID-19, Cancer Interactions

September 15, 2020

As COVID-19 alters current approaches to caring for patients with cancer, early emerging research data reinforce what practicing oncologists have been observing in their patients are at increased risk of mortality.